Tarsus Pharmaceuticals
TARS
253 hedge funds and large institutions have $3.17B invested in Tarsus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 88 increasing their positions, 82 reducing their positions, and 36 closing their positions.
33% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 36
31% more call options, than puts
Call options by funds: $19.2M | Put options by funds: $14.6M
3% more funds holding
Funds holding: 246 → 253 (+7)
2.3% more ownership
Funds ownership: 103.77% → 106.07% (+2.3%)
7% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 82
12% less capital invested
Capital invested by funds: $3.61B → $3.17B (-$439M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$41.6M |
| 2 |
Millennium Management
New York
|
+$31.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$30.5M |
| 4 |
Janus Henderson Group
London,
|
+$21.7M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$36.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$18.9M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$17.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17M |
| 5 |
BlackRock
New York
|
-$16.6M |
TARS Hedge Fund Activity: Q1 2026 in Review
253 of the 8,137 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q1 2026, worth a combined $3.17B — down 12% from $3.61B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new TARS positions and 36 closed out — a net gain of 12 holders — while 88 added to existing stakes and 82 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $41.6M. The largest seller was Jennison Associates, cutting an estimated $36.2M.
- 253 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q1 2026, up from 246 in Q4 2025.
- Funds reported $3.17B of Tarsus Pharmaceuticals stock for Q1 2026, down 12% quarter-over-quarter.
- 48 funds opened new Tarsus Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of +12 holders.
- The largest Tarsus Pharmaceuticals buyer in Q1 2026 was Deep Track Capital, an estimated $41.6M added.
- The largest Tarsus Pharmaceuticals seller in Q1 2026 was Jennison Associates, an estimated $36.2M sold.
Based on aggregated 13F filings for Q1 2026.